Fennec Pharmaceuticals Inc.
FRX.TO
TSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 88.89% | 43.24% | -109.08% | 25.99% | -207.18% |
| Total Depreciation and Amortization | 4.00% | -3.85% | -96.40% | -- | -- |
| Total Amortization of Deferred Charges | -42.86% | -43.48% | -35.00% | 1,178.57% | -70.83% |
| Total Other Non-Cash Items | -91.24% | 98.35% | -45.13% | 92.05% | 301.67% |
| Change in Net Operating Assets | 155.92% | 23.81% | -117.05% | 102.15% | -9.64% |
| Cash from Operations | 167.68% | 56.05% | -111.06% | 69.67% | 20.07% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -40.83% | 6.69% | -- |
| Repurchase of Common Stock | 90.53% | -215.56% | 36.84% | 47.06% | -3,671.43% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 431.25% | -210.51% | 131.71% | -313.12% | -362.69% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 218.58% | 51.17% | -110.44% | -1,673.10% | -6.84% |